MedTrace Logo

A Study of Quintuple Therapy to Treat COVID-19 Infection

NCT04334512 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2024-02-29

No results posted yet for this study

Summary

This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).

Conditions

  • COVID-19
  • Corona Virus Infection
  • Coronavirus-19
  • Sars-CoV2

Interventions

DRUG

Hydroxychloroquine

Treatment with hydroxychloroquine

DRUG

Azithromycin

Treatment with azithromycin

DIETARY_SUPPLEMENT

Vitamin C

Treatment with vitamin C

DIETARY_SUPPLEMENT

Vitamin D

Treatment with vitamin D

DIETARY_SUPPLEMENT

Zinc

Treatment with Zinc

Sponsors & Collaborators

  • DSCS CRO

    collaborator INDUSTRY

  • ProgenaBiome

    lead OTHER

Principal Investigators

  • Sabine Hazan, MD · ProgenaBiome

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-22
Primary Completion
2024-02-27
Completion
2024-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04334512 on ClinicalTrials.gov